Ocena zależności między ciśnieniem centralnym w aorcie a zesztywniającym zapaleniem stawów kręgosłupa

Introduction. Ankylosing spondylitis (AS) is a chronic inflammatory disease with an unknown etiology that belongs to the group of spondyloarthropathies. Patients with AS have an increased cardiovascular mortality but the reason is controversial. Central aortic pressure (CAP) is defined as the blood pressure in the aortic root and can be measured non-invasively via arteriography. Inflammation in the aortic root, which also causes aortic regurgitation in late sta ges of AS, possibly causes increased levels of central aortic pressure and this may explain the increased mortality rates from cardiovascular events in patients with AS. We investigated the CAP levels in patients with AS compared to healthy age- and sex-matched control group in this novel study. Material and methods. This is an observational case-control study composed of 30 patients with ankylosing spondylitis without conventional cardiovascular risk factors (such as known diabetes, hypertension, and smoking) or heart failure, peripheral or coronary artery disease. The peripheral blood pressures and CAP measurements were obtained with ‘arteriograph’ (TensioMed, Budapest, Hungary).Pulse wave velocity (PWV), peripheral and central augmentation index (pAIx and cAIx) and systolic central aortic pressure (sCAP) of both the AS and control group were compared. Results. There was no statistically significant difference between the groups for pAIx, cAIx, PWV or PP. Patient with AS had higher sCAP values but there wasn’t any statistically significant difference for sCAP. Conclusion. Our objective was to investigate the relationship between the AS and sCAP. There was an increase in sCAP in AS group compared to controls. But this was not statistically significant. This result can be due to the small population size and should be verified in larger population.Wstęp. Zesztywniające zapalenie stawów kręgosłupa (AS) to przewlekła choroba zapalna o nieznanej etiologii należąca do spondyloartropatii. U chorych z AS obserwuje się zwiększoną śmiertelność sercowo-naczyniową, jednak przyczyny tego zjawiska nie są znane. Ciśnienie centralne w aorcie (CAP) jest definiowane jako ciśnienie krwi w korzeniu aorty. Możliwy jest nieinwazyjny pomiar CAP metodą arteriografii. Zapalenie w obrębie korzenia aorty, będące również przyczyną niedomykalności w późnym stadium AS, może powodować wzrost ciśnienia centralnego w aorcie, co może tłumaczyć zwiększoną śmiertelność z powodu zdarzeń sercowo-naczyniowych w grupie chorych z AS. Autorzy zbadali wartości CAP u chorych z AS w porównaniu z wartościami uzyskanymi w grupie kontrolnej złożonej ze zdrowych osób dobranych pod względem wieku i płci. Materiał i metody. Tym obserwacyjnym badaniem kliniczno-kontrolnym objęto 30 chorych z AS, u których nie występowały tradycyjne czynniki ryzyka sercowo-naczyniowego (rozpoznana cukrzyca, nadciśnienie tętnicze, palenie tytoniu), niewydolność serca, choroba tętnic obwodowych ani choroba wieńcowa. Wartości obwodowego ciśnienia tętniczego i pomiary CAP uzyskano metodą arteriografii (TensioMed, Budapeszt, Węgry). Porównano wartości następujących parametrów w grupie AS i grupie kontrolnej: szybkość fali tętna (PWV), wskaźnik wzmocnienia ciśnienia obwodowego i centralnego (pAIx, cAIx) i skurczowe ciśnienie centralne w aorcie (sCAP). Wyniki. Nie stwierdzono statystycznie istotnych różnic między grupami pod względem wartości pAIx, cAIx, PWV ani PP. U chorych z AS zaobserwowano wyższe wartości sCAP, jednak różnice nie osiągnęły poziomu istotności statystycznej. Wnioski. Badanie przeprowadzono w celu zbadania zależności między AS a sCAP. W grupie chorych na AS wartości sCAP były wyższe niż w grupie kontrolnej. Jednak różnice nie były istotne statystycznie. Wyniki te mogą być spowodowane niewielką liczebnością badanej populacji i powinny zostać zweryfikowane w badaniu z większą liczbą uczestników

Heart rate turbulence analysis in female patients with fibromyalgia

OBJECTIVE: Fibromyalgia is characterized by diffuse musculoskeletal pain and discomfort. There are several reports regarding autonomic nervous system dysfunction in patients with fibromyalgia. Heart rate turbulence is expressed as ventriculophasic sinus arrhythmia and has been considered to reflect cardiac autonomic activity. Heart rate turbulence has been shown to be an independent and powerful predictor of sudden cardiac death in various cardiac abnormalities. The aim of this study is to determine whether heart rate turbulence is changed in female patients with fibromyalgia compared with healthy controls. METHODS: Thirty-seven female patients (mean age, 40±11 years) with fibromyalgia, and 35 age- and sex-matched healthy female control subjects (mean age, 42±9 years) were included. Twenty-four hours of ambulatory electrocardiography recordings were collected for all subjects, and turbulence onset and turbulence slope values were automatically calculated. RESULTS: The baseline clinical characteristics of the two groups were similar. There were no significant differences in turbulence onset and turbulence slope measures between patients and control subjects (turbulence onset: −1.648±1.568% vs. −1.582±1.436%, p ϝ 0.853; turbulence slope: 12.933±5.693 ms/RR vs. 13.639±2.505 ms/RR, p ϝ 0.508). Although body mass index was negatively correlated with turbulence slope (r ϝ −0.258, p ϝ 0.046), no significant correlation was found between body mass index and turbulence onset (r ϝ 0.228, p ϝ 0.054). CONCLUSION: To the best of our knowledge, this is the first study to evaluate heart rate turbulence in patients with fibromyalgia. It appears that heart rate turbulence parameters reflecting cardiac autonomic activity are not changed in female patients with fibromyalgia

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Acquired long QT syndrome related with ciprofloxacine usage

Hayatı tehdit eden ventriküler aritmilere sebep olabilen uzun QT sendromu doğumsal veya edinsel nedenlere bağlı olarak ortaya çıkabilmektedir. Günümüzde yaygın olarak kullanılmakta olan histamin 1 (H-1) reseptör antagonistleri ve florokinolon grubu antibiyotikler de edinsel uzun QT sendromuna neden olabilen ilaç gruplarındandır. Florokinolon grubu antibiyotikler doz bağımlı olarak gecikmiş düzenleyici potasyum akımının hızlı bile- şenini bloke ederler ve bu etkileri ile QT mesafesinde uzamaya ve torsades de pointes’e (TdP) neden olabilirler. Bu grup antibiyotiklerden olan siprofloksasinin de nadir de olsa QT mesafesini uzatabildiği ve TdP’ye neden olabildiği bilinmektedir ve bu etkisi diğer kinolonlarla kıyaslandığında daha nadir gözlenmektedir. Bizim olgumuzda da hem H-1 reseptör antagonisti olan hidroksizin hem de florokinolon grubu bir antibiyotik olan siprofloksasin kullanmaktayken edinsel uzun QT sendromu oluşmuştur.The long QT syndrome which can cause life threaten ventricular arrhythmias should be constituted due to congenital and acquired reasons. The histamine-1 (H-1) receptor antagonists and fluoroquinolone group antibiotics which are using frequently today are the members of drug groups that can cause acquired long QT syndrome. Fluoroquinolone group antibiotics blockade the fast component of delayed regulator potassium flow depend on dose and by this effect they can lengthen QT interval and can cause torsades de pointes (TdP). Ciprofloxacin, a member of this antibiotic group should lengthen QT interval and cause TdP rarely and this effects of ciprofloxacin are less common comparing with other quinolones. Acquired long QT syndrome appeared in our case while she was taking both hydroxyzine which is an H-1 receptor antagonist and ci